A Phase 2 interventional study of Saroglitazar magnesium 2 mg and Saroglitazar magnesium 4 mg in Primary Biliary Cirrhosis, sponsored by Zydus Therapeutics Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 40th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 37th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
Ipsen · Sites in United States
Women only
Zydus Therapeutics Inc. · Sites in United States
Ages 18+
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 18 · Phase 4 3
First in 1994; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 46 across the 65 interventional studies, 430 across the 17 observational. Of the 61 that completed or were terminated, 33 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zydus Therapeutics Inc., one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Zydus Lifesciences Limited has 6 studies filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis, Biliary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06427395Phase 3Zydus Therapeutics Inc.Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | 2027-04-18 |
| NCT06825559Zydus Therapeutics Inc.Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | 2026-12-31 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07631442Stanford UniversityUsing Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis (PBC). A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.
Study SARO.16.004.02 is a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis.
A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo. The primary objective is to investigate the effect of a 16-week treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on alkaline phosphatase (ALP) levels in patients with Primary Biliary Cholangitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a) Patients on therapeutic doses of Ursodeoxycholic acid (UDCA) for ≥12 months and stable therapy for ≥3 months prior to enrolment.
OR b) Patients who are unable to tolerate UDCA, and did not receive UDCA for at least 3 months from the date of screening.
History of confirmed Primary Biliary Cholangitis Diagnosis, based on American Association for the Study of Liver Disease [AASLD] and European Association for Study of the Liver [EASL] Practice Guidelines; [Lindor 2009; EASL 2009], as demonstrated by the presence of at least≥2 of the following 3 diagnostic factors:
Exclusion Criteria:
History or presence of other concomitant liver diseases including:
Unstable cardiovascular disease, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
Drug: Saroglitazar magnesium 2 mg
Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
Drug: Saroglitazar magnesium 4 mg
Placebo tablet Once daily for 16 weeks
Drug: Placebo Oral Tablet
Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
Also known as: Not any
Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
Also known as: Not any
Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
Also known as: Not any
Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.
Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.
Time frame: Baseline and Week 16
| Milestone | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Started | 14 | 13 | 10 |
| Completed | 13 | 10 | 9 |
| Not completed | 1 | 3 | 1 |
Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.
| U/L | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis. | -163.82 ± 111.84 | -162.31 ± 113.98 | -11.15 ± 27.36 |
Collected over 16 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saroglitazar Magnesium 2 mg | 0/14 (0%) | 2/14 (14.3%) | 12/14 (85.7%) |
| Saroglitazar Magnesium 4 mg | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Event | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 1/14 | 0/13 | 0/10 |
| AppendicitisInfections and infestations | 1/14 | 0/13 | 0/10 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/14 | 0/13 | 0/10 |
| Event | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 0/14 | 0/13 | 2/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/14 | 0/13 | 2/10 |
| NauseaGastrointestinal disorders | 1/14 | 2/13 | 1/10 |
| NasopharyngitisInfections and infestations | 1/14 | 2/13 | 0/10 |
| Hepatic Enzyme increasedInvestigations | 0/14 | 2/13 | 0/10 |
| ConstipationGastrointestinal disorders | 2/14 | 1/13 | 0/10 |
| DyspepsiaGastrointestinal disorders | 2/14 | 0/13 | 1/10 |
| Urinary tract infectionInfections and infestations | 2/14 | 1/13 | 0/10 |
| Transaminase increasedInvestigations | 2/14 | 0/13 | 0/10 |
| DiarrheaGastrointestinal disorders | 1/14 | 1/13 | 1/10 |
| Age, Continuous(Years) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 57.21 ± 9.67 | 55.08 ± 8.00 | 59.20 ± 7.30 | 57.00 ± 8.44 |
| Sex: Female, Male(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 13 | 13 | 10 | 36 |
| Male | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 0 | 4 |
| Not Hispanic or Latino | 10 | 12 | 10 | 32 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 13 | 11 | 9 | 33 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Mass Index(kg/m^2) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.71 ± 6.39 | 29.62 ± 6.49 | 32.30 ± 7.37 | 29.62 ± 6.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Aug 2020, 35 months.
Results were first posted in Sep 2024, 4 years 1 month after primary completion.
Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 35 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saroglitazar